Cost-Benefit Analysis Comparing Trough, Two-Level AUC, and Bayesian AUC Dosing for Vancomycin': Authors' Reply

Authors

Brian V. Lee, University of Southern California
Gary Fong, Chapman UniversityFollow
Michael Bolaris, Harbor-UCLA Medical Center
Michael Neely, Children's Hospital Los Angeles
Emi Minejima, University of Southern California
Amy Y. Kang, Chapman UniversityFollow
Grace Lee, Harbor-UCLA Medical Center
Cynthia L. Gong, University of Southern California

Document Type

Response or Comment

Publication Date

1-30-2021

Abstract

"Our response to your letter will address the two primary concerns in sequential order: the first concern being the Bayesian AUC to trough comparison, and the second being two-level AUC to trough."

Comments

This article was originally published in Clinical Microbiology and Infection, volume 27, issue 6, in 2021. https://doi.org/10.1016/j.cmi.2021.01.015

Recommended Citation

Lee BV, Fong G, Bolaris M, et al. 'Cost-benefit analysis comparing trough, two-level AUC, and Bayesian AUC dosing for vancomycin': authors' reply. Clin Microbiol Infect. 2021;27(6):929-930. https://doi.org/10.1016/j.cmi.2021.01.015

Copyright

Elsevier